Science:逆转录转座子在肿瘤发生中的重要作用

2012-07-02 songbo 本站原创

6月28日,Science杂志在线报道了关于体细胞逆转录转座子在人类肿瘤发生中作用的最新研究进展。 转座子(TEs)在人类基因组中含量丰富,有些能够通过RNA中间体产生新的插入序列。在癌症细胞中,通常抑制TE活动的机制如果遭到破坏,可能会促进诱导突变的逆转录转座子的产生。研究者对五个类型的癌症中 43个高覆盖率全基因组测序数据集的TE插入序列,进行了单个核苷酸分辨率的分析。 研究确定了194个

6月28日,Science杂志在线报道了关于体细胞逆转录转座子在人类肿瘤发生中作用的最新研究进展。

转座子(TEs)在人类基因组中含量丰富,有些能够通过RNA中间体产生新的插入序列。在癌症细胞中,通常抑制TE活动的机制如果遭到破坏,可能会促进诱导突变的逆转录转座子的产生。研究者对五个类型的癌症中 43个高覆盖率全基因组测序数据集的TE插入序列,进行了单个核苷酸分辨率的分析。

研究确定了194个高可信度TE插入序列,以及与之相应的正常基因组中,数千个多态性TE插入序列。体细胞插入序列存在于上皮性肿瘤,而不在血液或脑肿瘤中。体细胞L1插入序列往往发生在癌症中常见的突变基因中。该插入序列破坏靶基因的表达,偏爱出现于癌症特异性DNA低甲基化的区域。这些现象表明,体细胞L1插入序列在肿瘤发生的潜在的重要影响。

doi:10.1016/j.cell.2011.10.017
PMC:

PMID:

Landscape of Somatic Retrotransposition in Human Cancers

Eunjung Lee1,2, Rebecca Iskow3, Lixing Yang1, Omer Gokcumen3, Psalm Haseley1,2, Lovelace J. Luquette III1, Jens G. Lohr4,5, Christopher C. Harris6, Li Ding6, Richard K. Wilson6, David A. Wheeler7, Richard A. Gibbs7, Raju Kucherlapati2,8, Charles Lee3, Peter V. Kharchenko1,9,*, Peter J. Park1,2,9,*, The Cancer Genome Atlas Research Network

Transposable elements (TEs) are abundant in the human genome, and some are capable of generating new insertions through RNA intermediates. In cancer, the disruption of cellular mechanisms that normally suppress TE activity may facilitate mutagenic retrotranspositions. We performed single-nucleotide resolution analysis of TE insertions in 43 high-coverage whole-genome sequencing data sets from five cancer types. We identified 194 high-confidence somatic TE insertions, as well as thousands of polymorphic TE insertions in matched normal genomes. Somatic insertions were present in epithelial tumors but not in blood or brain cancers. Somatic L1 insertions tend to occur in genes that are commonly mutated in cancer, disrupt the expression of the target genes, and are biased toward regions of cancer-specific DNA hypomethylation, highlighting their potential impact in tumorigenesis.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2023448, encodeId=6aa5202344891, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Sun Aug 12 17:09:00 CST 2012, time=2012-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747163, encodeId=f1ca1e47163ce, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Thu Dec 06 09:09:00 CST 2012, time=2012-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926815, encodeId=6ffc19268155b, content=<a href='/topic/show?id=09d594e5610' target=_blank style='color:#2F92EE;'>#逆转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94756, encryptionId=09d594e5610, topicName=逆转录)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Sun Nov 25 15:09:00 CST 2012, time=2012-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936054, encodeId=0813193605451, content=<a href='/topic/show?id=304c933406f' target=_blank style='color:#2F92EE;'>#转座子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93340, encryptionId=304c933406f, topicName=转座子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Fri Oct 26 17:09:00 CST 2012, time=2012-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374655, encodeId=bfb613e46557c, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Wed Jul 04 09:09:00 CST 2012, time=2012-07-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2023448, encodeId=6aa5202344891, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Sun Aug 12 17:09:00 CST 2012, time=2012-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747163, encodeId=f1ca1e47163ce, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Thu Dec 06 09:09:00 CST 2012, time=2012-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926815, encodeId=6ffc19268155b, content=<a href='/topic/show?id=09d594e5610' target=_blank style='color:#2F92EE;'>#逆转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94756, encryptionId=09d594e5610, topicName=逆转录)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Sun Nov 25 15:09:00 CST 2012, time=2012-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936054, encodeId=0813193605451, content=<a href='/topic/show?id=304c933406f' target=_blank style='color:#2F92EE;'>#转座子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93340, encryptionId=304c933406f, topicName=转座子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Fri Oct 26 17:09:00 CST 2012, time=2012-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374655, encodeId=bfb613e46557c, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Wed Jul 04 09:09:00 CST 2012, time=2012-07-04, status=1, ipAttribution=)]
    2012-12-06 mjldent
  3. [GetPortalCommentsPageByObjectIdResponse(id=2023448, encodeId=6aa5202344891, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Sun Aug 12 17:09:00 CST 2012, time=2012-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747163, encodeId=f1ca1e47163ce, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Thu Dec 06 09:09:00 CST 2012, time=2012-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926815, encodeId=6ffc19268155b, content=<a href='/topic/show?id=09d594e5610' target=_blank style='color:#2F92EE;'>#逆转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94756, encryptionId=09d594e5610, topicName=逆转录)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Sun Nov 25 15:09:00 CST 2012, time=2012-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936054, encodeId=0813193605451, content=<a href='/topic/show?id=304c933406f' target=_blank style='color:#2F92EE;'>#转座子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93340, encryptionId=304c933406f, topicName=转座子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Fri Oct 26 17:09:00 CST 2012, time=2012-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374655, encodeId=bfb613e46557c, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Wed Jul 04 09:09:00 CST 2012, time=2012-07-04, status=1, ipAttribution=)]
    2012-11-25 hxj0117
  4. [GetPortalCommentsPageByObjectIdResponse(id=2023448, encodeId=6aa5202344891, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Sun Aug 12 17:09:00 CST 2012, time=2012-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747163, encodeId=f1ca1e47163ce, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Thu Dec 06 09:09:00 CST 2012, time=2012-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926815, encodeId=6ffc19268155b, content=<a href='/topic/show?id=09d594e5610' target=_blank style='color:#2F92EE;'>#逆转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94756, encryptionId=09d594e5610, topicName=逆转录)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Sun Nov 25 15:09:00 CST 2012, time=2012-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936054, encodeId=0813193605451, content=<a href='/topic/show?id=304c933406f' target=_blank style='color:#2F92EE;'>#转座子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93340, encryptionId=304c933406f, topicName=转座子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Fri Oct 26 17:09:00 CST 2012, time=2012-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374655, encodeId=bfb613e46557c, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Wed Jul 04 09:09:00 CST 2012, time=2012-07-04, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2023448, encodeId=6aa5202344891, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Sun Aug 12 17:09:00 CST 2012, time=2012-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747163, encodeId=f1ca1e47163ce, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Thu Dec 06 09:09:00 CST 2012, time=2012-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926815, encodeId=6ffc19268155b, content=<a href='/topic/show?id=09d594e5610' target=_blank style='color:#2F92EE;'>#逆转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94756, encryptionId=09d594e5610, topicName=逆转录)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Sun Nov 25 15:09:00 CST 2012, time=2012-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936054, encodeId=0813193605451, content=<a href='/topic/show?id=304c933406f' target=_blank style='color:#2F92EE;'>#转座子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93340, encryptionId=304c933406f, topicName=转座子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Fri Oct 26 17:09:00 CST 2012, time=2012-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374655, encodeId=bfb613e46557c, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Wed Jul 04 09:09:00 CST 2012, time=2012-07-04, status=1, ipAttribution=)]
    2012-07-04 jichang

相关资讯

2010年中国科技论文统计出炉,生物医药领域表现不俗

中国科技信息研究所(下称中信所)12月2日对外发布了2010年中国科技论文(下称国际论文)统计结果。 2010年,我国机构作者为第一作者发表的国际论文共12.15万篇,其中23968篇论文的被引用次数高于学科均线,即其论文发表后的影响超过其所在学科的一般水平,也就是说占我国论文总数的19.7%的论文表现不俗,该比例较2009年的15.5%上升了4.2个百分点。我国表现不俗的论文 81.6%由

Science:科学家发现导致青蒿素耐药性元凶

4月6日,Science发表的一项研究结果表明,疟疾寄生虫基因组中的一个区域可能是目前最有效的疟疾疗法产生耐药性的“元凶”。这一发现所涉及的耐药性似乎正在东南亚地区蔓延。 在疟疾流行的任何地方,青蒿素已经成为绝对的“主打”疗法。有关青蒿素的耐药性最早于2005年在柬埔寨西部首次被发现。这种耐药性并不会导致青蒿素治疗的彻底失败,但它却减缓了清除患者血液中导致疟疾的恶性疟原虫(Plasmodium